Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2
30 participants
INTERVENTIONAL
2021-04-07
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Mechanism of action is not fully elucidated but improved keratinocyte migration and suppression of the inflammatory cascade is thought to improve wound healing. Skin cancer surgeries have morbidity for patients as they are often in cosmetically sensitive locations. Improving cosmetic outcomes of surgical scars could improve patient outcomes and overall satisfaction.
The goal of this study is to determine if topical timolol will improve long-term cosmetic outcomes of surgical scars and thereby improve patient outcomes. There is great variability in how a surgical site heals depending on patient factors as well as surgical site location. The investigators will perform a split scar study to allow each patient to be their own control to account for this variability.
To assess the efficacy and safety of topically applied 0.25% timolol in promoting wound healing in surgical primary linear wound greater than or equal to 4cm versus standard of care (SOC) by:
1. Evaluating cosmetic outcomes of surgical wounds in terms of blinded physician and patient assessment at 30 days and 90days following suture removal
2. Evaluating patient discomfort by patient questionnaire.
3. Determining the side effects associated to 0.25% topical timolol versus SOC;
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Timolol
Timolol 0.25% applied to distal or posterior half of wound edge twice daily prior and adjunct to prior wound care.
Timolol 0.25% Ophthalmic Solution
Applied to treatment side prior to standard wound care
Standard Wound Care
Petrolatum ointment
Standard Wound Care
Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Timolol 0.25% Ophthalmic Solution
Applied to treatment side prior to standard wound care
Standard Wound Care
Wound is washed twice a day with soap and then petrolatum and a bandage is applied.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* known history of sensitivity to beta blockers or topical timolol
* pregnant women
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Keith G. LeBlanc, Jr, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Keith G. LeBlanc, Jr, MD
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Keith G LeBlanc, MD
Role: PRINCIPAL_INVESTIGATOR
LSU HSC New Orleans
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Skin Surgery Centre
Metairie, Louisiana, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Taylor G Dickerson, MD
Role: primary
Keith Leblanc, MD
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Jeha GM, Dickerson T, Hargrave L, Bao-Loc-Trung M, Prusisz T, Bucher E, Rougelot RC, LeBlanc K Jr. Does Timolol Solution Improve the Appearance of Acute Surgical Wounds After Mohs Surgery? A Split-Scar Clinical Study. Dermatol Surg. 2024 May 1;50(5):481-483. doi: 10.1097/DSS.0000000000004094. Epub 2024 Jan 23. No abstract available.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1227
Identifier Type: -
Identifier Source: org_study_id